Willfact

Willfact Human Von Willebrand Factor is a plasma-derived treatment for von Willebrand disease. Administered intravenously, it helps manage bleeding episodes and surgical prophylaxis. Suitable for patients requiring VWF replacement therapy. EU-sourced and manufactured by Lfb Biomedicaments.

Willfact Human Von Willebrand Factor is used to treat and prevent bleeding in patients with von Willebrand disease, a genetic bleeding disorder. It provides the missing or dysfunctional von Willebrand factor protein, supporting normal blood clotting. Often prescribed for routine prophylaxis or during surgical procedures to reduce bleeding risk. May also be used in acquired von Willebrand syndrome where natural levels are insufficient.

Willfact works by temporarily restoring von Willebrand factor levels in the bloodstream, supporting platelet adhesion and clot formation. Users may experience reduced frequency or severity of bleeding episodes after administration. The product is designed to mimic the body’s natural clotting process, though individual responses may vary. Effects are typically observed within hours of intravenous infusion.

Store Willfact Human Von Willebrand Factor as directed, typically refrigerated at 2–8°C (36–46°F), and protect from light. Do not freeze. Follow aseptic technique during preparation and administration to prevent contamination. Discard any unused product or diluent after the recommended timeframe. Keep out of reach of children and pets.

Willfact may interact with medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. Concurrent use with fibrinolytic agents could reduce efficacy. Always inform healthcare providers about all medications being taken. No known interactions with common over-the-counter supplements or foods have been established.